source
- Johnson & Johnson’s Global Chair of Innovative Medicine Jennifer Taubert Announces RetirementJennifer Taubert, who leads Johnson & Johnson Innovative Medicine worldwide, has said she will step down from her role later this year. The company indicated that Tom (last name not disclosed) wil…
- BioMarin halts development of BMN401 enzyme therapy after mixed Phase 3 resultsBioMarin announced it will stop work on BMN401, an enzyme replacement therapy aimed at treating ENPP1 deficiency, a rare genetic disorder. The decision follows a Phase 3 trial that produced mixed…